Wall Street analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from ($0.15) to ($0.08). Vanda Pharmaceuticals posted earnings of ($0.01) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1,100%. The company is scheduled to announce its next earnings report on Wednesday, February 21st.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.39). For the next financial year, analysts forecast that the company will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.72) to $0.04. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. During the same period last year, the company posted ($0.01) EPS. Vanda Pharmaceuticals’s revenue was up 7.3% on a year-over-year basis.
Several brokerages have issued reports on VNDA. Oppenheimer reaffirmed a “buy” rating and issued a $25.00 target price on shares of Vanda Pharmaceuticals in a report on Sunday, November 12th. Piper Jaffray Companies lifted their target price on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, October 18th. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.50.
Vanda Pharmaceuticals (VNDA) opened at $15.25 on Thursday. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99. The stock has a market cap of $682.90, a PE ratio of -47.66 and a beta of 1.28.
Several hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC grew its stake in shares of Vanda Pharmaceuticals by 221.3% in the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 17,485 shares during the period. University of Notre Dame DU Lac bought a new stake in shares of Vanda Pharmaceuticals in the third quarter worth approximately $2,824,000. Schwab Charles Investment Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 2.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock worth $8,459,000 after acquiring an additional 11,647 shares during the period. Wells Fargo & Company MN grew its stake in shares of Vanda Pharmaceuticals by 112.2% in the third quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after acquiring an additional 80,209 shares during the period. Finally, Cadence Capital Management LLC bought a new stake in Vanda Pharmaceuticals during the third quarter valued at approximately $1,121,000. Hedge funds and other institutional investors own 88.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/12/vanda-pharmaceuticals-inc-vnda-expected-to-post-earnings-of-0-12-per-share-2.html.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.